Compositions and methods for treating cancer with atypical BRAF mutations
AssigneeBiomed Valley Discoveries, Inc.
InventorsGary DeCrescenzo, Dean Welsch, Saurabh Saha
Life of this patent
Estimating the term…
Abstract
The present invention provides, inter alia, methods, pharmaceutical compositions, and kits for treating or ameliorating the effects of a cancer in a subject, which harbors an atypical BRAF mutation (i.e. a non-V600E/K BRAF mutation), comprising an ERK inhibitor. Also provided are methods for identifying a subject having an atypical BRAF mutant cancer who would benefit from therapy comprising an ERK inhibitor.
Claims30
A method for treating or ameliorating the effects of a cancer in a subject harboring a non-V600E/K BRAF mutation, the method comprising administering to the subject an effective amount of an ERK inhibitor or a pharmaceutically acceptable salt thereof,
- wherein the non-V600E/K BRAF mutation is selected from the group consisting of L485W, F247L, BRAF-AGAP3 rearrangement, BRAF exon 15 splice variant, and combinations thereof, and
- wherein the ERK inhibitor is selected from the group consisting of BVD-523, SCH-722984, SCH-772984, SCH-900353, LY3214996, AEZS-140, AEZS-131, AEZS-136, LTT-462, RG-7842, CC-90003, KIN-4050, and combinations thereof.
A method for treating or ameliorating the effects of a cancer in a subject comprising the steps of:
- (a) identifying a subject with a cancer harboring a non-V600E/K BRAF mutation, wherein the non-V600E/K BRAF mutation is selected from the group consisting of L485W, F247L, BRAF-AGAP3 rearrangement, BRAF exon 15 splice variant, and combinations thereof;
- and
- (b) administering to the subject an effective amount of an ERK inhibitor or a pharmaceutically acceptable salt thereof, wherein the ERK inhibitor is selected from the group consisting of BVD-523, SCH-722984, SCH-772984, SCH-900353, LY3214996, AEZS-140, AEZS-131, AEZS-136, LTT-462, RG-7842, CC-90003, KIN-4050, and combinations thereof.
A method for treating or ameliorating the effects of a cancer in a subject harboring a non-V600E/K BRAF mutation, the method comprising administering to the subject an effective amount of BVD-523 or a pharmaceutically acceptable salt thereof,
- wherein the non-V600E/K BRAF mutation is selected from the group consisting of L485W, F247L, BRAF-AGAP3 rearrangement, BRAF exon 15 splice variant, and combinations thereof.
A method for treating or ameliorating the effects of a cancer in a subject comprising:
- (a) identifying a subject with a cancer harboring a non-V600E/K BRAF mutation, wherein the non-V600E/K BRAF mutation is selected from the group consisting of L485W, F247L, BRAF-AGAP3 rearrangement, BRAF exon 15 splice variant, and combinations thereof;
- and
- (b) administering to the subject an effective amount of BVD-523 or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.